Quality assurance of malaria microscopy is an important issue in health service and health research for a better case management. In monitoring Dyhydroartemisinin-Piperaquine, quality assurance was a part of this research activities at sentinel sites in Kalimantan and Sulawesi. This activity was carried out to confirmed diagnosis of malaria cases that could be analysed, and to evaluate the skil…
Treatment failure in falciparum malaria may be caused by parasite resistant to antimalarial drug or new infection. Polymorphism genetic marker of P. falciparum namely MSP1, MSP2 and GLURP locus genes in the population should be identified as a baseline to distinguish the cause of treatment failure. A nested Polymerase Chain Reaction (PCR) method was applied to each locus gene separately. A tota…
This study was a part of the activity of monitoring Dihydroartemisinin-Piperaquine (DHP) treatment in subjects infected with P.falciparum and P.vivax in Kalimantan and Sulawesi. SNP Y976F had been proved as the mutation in pvmdr1 gene which was related to P. vivax resistance chloroquine in Papua. Data of spreading pvmdr1 SNP Y976F outside Papua is needed for using Dihidroartemisinin-Piperakuin …
In monitoring the treatment of malaria with Dihydroartemisinin-piperaquine (DHP), microscopic cross check and Polymerase Chain Reaction (PCR) performed to validate the results of laboratory examinations in the field. This study used finger prick samples from subjects with a diagnosis of malaria in monitoring the treatment of malaria with DHP in Kalimantan and Sulawesi. Samples taken at day 0, b…
Drug resistance is one of the global problems, particularly in communicable diseases control including Indonesian malaria elimination program. Since 2004, Artesunate-Amodiaquine (AS+AQ), an Artemisinin based Combination Therapy (ACT), has been used in Indonesia as recommended by the WHO for treatment of acute uncomplicated malaria, replacing of chloroquine resistant antimalarial. Since then, im…